Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Resilience and Mayo team up on rare disease

by Rick Mullin
August 19, 2022 | A version of this story appeared in Volume 100, Issue 29

 

The pharmaceutical manufacturing and services firm National Resilience and the Mayo Clinic have announced a partnership to develop biologic therapies for rare diseases. Resilience will collaborate with Mayo’s Center for Regenerative Medicine in Rochester, Minnesota, where the partners plan to build process and analytical development laboratories for cell therapies and other modalities with the aim of advancing therapeutic candidates to early-stage clinical trials. Resilience and Mayo hope to attract biotechnology firms interested in collaborations and the sponsorship of clinical trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.